Inhibrx año OPV
¿Qué es el año OPV de Inhibrx?
El año OPV de Inhibrx, Inc. es 2020
¿Cuál es la definición de año OPV?
La oferta pública inicial es un tipo de oferta pública en la cual las acciones de una compañía generalmente se venden a inversionistas institucionales que, a su vez, venden al público en general, en una bolsa de valores, por primera vez.
Through IPO a privately held company transforms into a public company. Initial public offerings are mostly used by companies to raise the expansion of capital, possibly to monetize the investments of early private investors, and to become publicly traded enterprises. A company selling shares is never required to repay the capital to its public investors. After the IPO, when shares trade freely in the open market, money passes between public investors.
Although IPO offers many advantages, there are also significant disadvantages, chief among these are the costs associated with the process and the requirement to disclose certain information that could prove helpful to competitors.
The IPO process is colloquially known as going public. Details of the proposed offering are disclosed to potential purchasers in the form of a lengthy document known as a prospectus. Most companies undertake an IPO with the assistance of an investment banking firm acting in the capacity of an underwriter. Underwriters provide several services, including help with correctly assessing the value of shares.
año OPV de compañías en Sector Health Care en NASDAQ en comparadas con Inhibrx
¿Qué hace Inhibrx?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
Empresas con año opv similar a Inhibrx
- Acusensus Ltd tiene año OPV de 2019
- Grayscale Ethereum Trust (ETH) tiene año OPV de 2019
- Powerwrap Ltd tiene año OPV de 2019
- Powerwrap tiene año OPV de 2019
- National Rural Utilities Cooper tiene año OPV de 2019
- Listed Funds Trust tiene año OPV de 2019
- Inhibrx tiene año OPV de 2020
- Globally Local Technologies tiene año OPV de 2021
- uniQure N.V tiene año OPV de 2021
- Trustpilot plc tiene año OPV de 2021
- IQVIA tiene año OPV de 2021
- ACTIA S.A tiene año OPV de 2021
- Remark tiene año OPV de 2021